VEGFA and glioma: Collectively, the data indicate that treatment with imipramine reprograms—via inhibiting the histamine receptor Hrh1—both subtypes of glioma TAMs away from an M2-like immunosuppressive phenotype, thereby functionally contributing to the observed therapeutic benefit of imipramine in combination with VEGF inhibition.